Merck Merges With Schering-Plough

Merck & Co has outlined its global plans after Merk’s merger with Schering-Plough. The new Merck will be a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value.

By leveraging Merck’s expanded product offerings, the new company expects to benefit from additional revenue growth opportunities. Merck will pursue expanded life-cycle management through the introduction of potential new combinations and formulations of existing products.

The new Merck’s diverse portfolio of adult, adolescent and pediatric vaccines and medicines spans important therapeutic areas, including cardiovascular, diabetes, obesity, bone, respiratory, immunology, dermatology, infectious disease, oncology, neurosciences, ophthalmology, women’s health and endocrinology.

The new Merck’s expanded portfolio also includes products from its Animal Health and Consumer Health Care business units.

The organizational structure is expected to take advantage of the combined strengths of Merck and Schering-Plough to create a more customer-focused, innovative, and diversified global health care company positioned to capitalize on the company’s greatest opportunities for growth, particularly in emerging markets, biologics and vaccines.

Richard Clark, chairman, president and chief executive officer of Merck, said: “With our merger now complete, we are ready to deliver on the promise of a new Merck built on a foundation of scientific innovation and dedication to the well-being of patients around the world.

“Our integration teams prepared us well for a strong start, with thorough plans designed to ensure a seamless transition for our customers and employees. The combination of the considerable talents of Schering-Plough and Merck employees across the globe positions Merck to move through this dynamic time for our industry with a clear vision for the future.”